Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Dirk Kersten sold 40,831 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $35.32, for a total transaction of $1,442,150.92. Following the sale, the director now directly owns 193,296 shares of the company’s stock, valued at approximately $6,827,214.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Dirk Kersten also recently made the following trade(s):
- On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95.
Dyne Therapeutics Stock Performance
Shares of NASDAQ:DYN traded down $1.23 during midday trading on Tuesday, hitting $33.40. The company’s stock had a trading volume of 1,936,244 shares, compared to its average volume of 1,608,944. The stock’s 50 day simple moving average is $40.89 and its 200 day simple moving average is $33.71. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of -8.72 and a beta of 1.07. Dyne Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $47.45.
Institutional Investors Weigh In On Dyne Therapeutics
Several large investors have recently made changes to their positions in DYN. Algert Global LLC boosted its stake in Dyne Therapeutics by 255.1% in the 2nd quarter. Algert Global LLC now owns 97,370 shares of the company’s stock valued at $3,436,000 after purchasing an additional 69,947 shares during the period. The Manufacturers Life Insurance Company increased its position in Dyne Therapeutics by 96.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 126,244 shares of the company’s stock valued at $4,455,000 after acquiring an additional 61,902 shares during the period. AQR Capital Management LLC lifted its stake in shares of Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after acquiring an additional 352 shares during the period. Affinity Asset Advisors LLC bought a new stake in Dyne Therapeutics during the second quarter valued at $3,529,000. Finally, First Light Asset Management LLC increased its stake in shares of Dyne Therapeutics by 261.0% in the 2nd quarter. First Light Asset Management LLC now owns 382,433 shares of the company’s stock valued at $13,496,000 after acquiring an additional 276,485 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Piper Sandler restated an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a report on Monday. Oppenheimer reissued an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.
View Our Latest Research Report on DYN
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Stories
- Five stocks we like better than Dyne Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Fintech Stocks With Good 2021 Prospects
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How Can Investors Benefit From After-Hours Trading
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.